Overview

• MannKind Q3 2025 rev rises 17% yr/yr to $82.1 mln

• Adjusted EPS for Q3 2025 increases 45% from last year

• Company completes acquisition of scPharmaceuticals, boosting revenue growth

Outlook

• Company expects FUROSCIX sNDA review decision by end of 2025

• MannKind anticipates Afrezza pediatric sBLA decision by May 29, 2026

• Company plans to enroll first patient in MNKD-201 IPF trial in Q1 2026

Result Drivers

• ROYALTIES AND COLLABORATIONS - Revenue growth driven by increased royalties from Tyvaso DPI and higher collaborations and services revenue

• AFREZZA REVENUE - Afrezza revenue increased due to higher price and demand, despite a decrease in V-Go revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for MannKind Corp is $10.00, about 45.2% above its November 4 closing price of $5.48

• The stock recently traded at 62 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nGNX2dqwYK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)